Apollomics Inc. Warrant
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, … Read more
Apollomics Inc. Warrant (APLMW) - Net Assets
Latest net assets as of June 2024: $20.81 Million USD
Based on the latest financial reports, Apollomics Inc. Warrant (APLMW) has net assets worth $20.81 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.57 Million) and total liabilities ($13.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.81 Million |
| % of Total Assets | 60.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Apollomics Inc. Warrant - Net Assets Trend (2020–2023)
This chart illustrates how Apollomics Inc. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Apollomics Inc. Warrant (2020–2023)
The table below shows the annual net assets of Apollomics Inc. Warrant from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $41.23 Million | +109.20% |
| 2022-12-31 | $-448.12 Million | -110.52% |
| 2021-12-31 | $-212.86 Million | -66.39% |
| 2020-12-31 | $-127.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apollomics Inc. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50542200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.02% |
| Other Comprehensive Income | $26.72 Million | 64.79% |
| Other Components | $661.47 Million | 1604.20% |
| Total Equity | $41.23 Million | 100.00% |
Apollomics Inc. Warrant Competitors by Market Cap
The table below lists competitors of Apollomics Inc. Warrant ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SURNF
OTCQB:SURNF
|
$133.19 |
|
Anglo Philippine Holdings Corp
PSE:APO
|
$133.50 |
|
SCOA NIGERIA PLC
XNSA:SCOA
|
$133.60 |
|
Red Capital PLC
LSE:REDC
|
$133.84 |
|
Institute of Biomedical Research Corp
PINK:MRES
|
$132.71 |
|
Synergia Energy Ltd.
LSE:SYN
|
$132.62 |
|
CWG PLC
XNSA:CWG
|
$132.18 |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
$131.77 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apollomics Inc. Warrant's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -448,120,000 to 41,234,000, a change of 489,354,000.
- Net loss of 172,601,000 reduced equity.
- Other comprehensive income increased equity by 23,318,000.
- Other factors increased equity by 638,637,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-172.60 Million | -418.59% |
| Other Comprehensive Income | $23.32 Million | +56.55% |
| Other Changes | $638.64 Million | +1548.81% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Apollomics Inc. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1.47 | $0.01 | x |
| 2021-12-31 | $-2.45 | $0.01 | x |
| 2022-12-31 | $-5.16 | $0.01 | x |
| 2023-12-31 | $0.55 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apollomics Inc. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -418.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21023.26%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.34x
- Recent ROE (-418.59%) is below the historical average (-104.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -4070.73% | 0.01x | 0.00x | $-62.03 Million |
| 2021 | 0.00% | -4739850.00% | 0.00x | 0.00x | $-73.51 Million |
| 2022 | 0.00% | -74554.49% | 0.00x | 0.00x | $-196.00 Million |
| 2023 | -418.59% | -21023.26% | 0.01x | 1.34x | $-176.72 Million |
Industry Comparison
This section compares Apollomics Inc. Warrant's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apollomics Inc. Warrant (APLMW) | $20.81 Million | 0.00% | 0.66x | $132.88 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |